Navigating Your Toughest Price And Market Access Challenges

NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.

We help you plan and evaluate strategies to achieve success in U.S. and global markets.

Explore NAVLIN

Comprehensive. Intuitive. Integrated.

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Data

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Price & Access Software

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Insights

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Daily

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

NAVLIN Revenue Management

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Software

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Insights

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Daily

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Revenue Management

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

Experience the
NAVLIN difference

650+
Global sources monitored daily for price, HTA, policy and tender data
+99%
Accuracy of real-time reimbursement, HTA and tender data
<24
hours Speed of updates made from time of publication
4,000+
Medical and pharmacy decision-making executives included in NAVLIN Insights survey panels
24x7
Continuous operations and support
99.5%
Customer satisfaction with market research insights
Real quotes from real clients

Client Delight

This is an amazing tool. The data quality, insights, and user-friendliness are far superior to any other pricing database I’ve used in my career.

Enric Muñoz

Sr. Director, Global Strategic Pricing Head, Takeda

To say thank you seems so trivial. I really appreciate all the hard work and time that you all have invested.

Sr. Director, Global Strategic Pricing Head, Takeda

My team literally could not do what they do without this solution.

Sr. Director, Market Access

Intelligent, intuitive, insightful, helpful, and responsive!

US Payer & Channel Access, Pfizer

NAVLIN Daily News

Checkout Today’s News

Study Finds NICE's Decision-Making Impacts…

A new report by the Office of Health Economics (OHE) has found that decisions made by the UK's National Institute for Health and Care Excellence (NICE) play a significant role in international health technology assessment (HTA) decision-making, but its impact varies by countryThe report, titled "Do NICE's Decision Outcomes Impact International HTA Decision-making?", analyzed the potential impact of NICE's decisions on HTA bodies in 12 countries, Australia, Brazil, Canada, France, Italy, Israel, Japan, South Korea, Poland, Saudi Arabia, Sweden, and the United Arab EmiratesOne key finding from the study is that negative decisions from NICE carry significant weight, as they can trigger heightened scrutiny of submissions to other HTA agencies. Additionally, they often exert downward pressure on prices during negotiations, even if they don't directly shape the final HTA decision

Novartis Withdraws Tabrecta in Germany

Novartis has removed Tabrecta (capmatinib) from the market in Germany due to "issues" with the AMNOG system. In February, the Federal Joint Committee (G-BA) voted that the added benefit of Tabrecta was "not proven" for treating advanced non-small cell lung cancer with specific genetic mutationsNovartis was then unable to reach an agreement with the GKV-Spitzenverband for a rebated price for Tabrecta, leading to its withdrawal from the German market. This could impact international reference pricing (IRP) practices for other countriesCurrent stocks of Tabrecta will last until around March 2024, allowing existing patients to continue their treatment. After that, the drug will be available only through named-patient schemes, requiring approval for reimbursement by health insurance funds

Dutch Government Contemplates Expanding IRP Basket to…

The Dutch Ministry of Finance is assessing the potential cost savings of broadening its international reference pricing (IRP) reference basket to encompass ten countries, and applying a rule based on the average of the three lowest-priced countries to determine the maximum drug priceCurrently, the maximum price is calculated based on the average prices in Belgium, the UK, Norway, and France. However, the change would include France, the UK, Denmark, Finland, Ireland, Norway, Austria, Sweden, Belgium, and GermanyThe potential changes are dependent on discussions following the election scheduled for November, 2023. While the proposals could save an estimated EUR 95 million per year, concerns have been raised by the Dutch Association for Innovative Medicines (VIG) about the impact on drug availability

Telethon Foundation Officially Takes on Strimvelis in…

The European Commission has approved the transfer of Strimvelis' marketing authorization from Orchard Therapeutics to the Telethon Foundation, ensuring that eligible patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) in the European Union will continue to receive the gene therapyOrchard Therapeutics had previously announced its intention to move away from gene therapy for primary immunodeficiencies, which put ADA-SCID patients at risk of losing access to treatment. The Telethon Foundation has stepped in to take on the responsibility of providing Strimvelis, despite it being a loss-making productFondazione Telethon will make Strimvelis available to eligible patients through the San Raffaele Hospital in Milan, Italy. The gene therapy, which was the first approved in the world for ex vivo gene therapy, is only approved in Europe and cannot be frozen or preserved, requiring the production site to be in close proximity to the administration site

Dutch Pharma Association Slams Ministry's Cost-Cutting…

The Dutch Association for Innovative Medicines (VIG) has strongly criticized the Ministry of Finance's latest proposals for cost-containment measures in the pharmaceutical sector, calling them a "disastrous menu of options for drug cuts”The measures, if implemented, could save the government up to EUR 1.1 billion annually, however, VIG raises concerns about patient access and the sustainability of the healthcare system“The measures lead to medicines disappearing from the market in the Netherlands and the serious risk that new medicines will no longer be offered in our country at all,” commented Wim de Haart, Health Economics and reimbursement Manager at VIG. “That's why I think political parties should scratch their heads before they consider introducing one or more of these measures”

Spain's MoH Opts to Exclude Economic Evaluations in…

Following a recent court ruling that annulled the 2020 Plan for the Consolidation of Therapeutic Positioning Reports (IPT), the Spanish Ministry of Health has chosen to exclude economic evaluations from its latest drug approvals, opting to comply with the court's decision while simultaneously studying ways to reintegrate the economic analysis componentThe National Court's ruling, issued in late July, came in response to an appeal by the association of the innovative pharmaceutical industry (Farmaindustria), in which the group argued that the Plan went beyond the scope of the law by regulating the procedure for the inclusion of a drug in public financing and pricing, imposing obligations that extended beyond the realm of the AdministrationFollowing the court's decision, the Ministry of Health announced that it was evaluating its response to the ruling, with the option to appeal still on the table. However, due to time constraints and the necessity of proceeding with drug approvals, certain actions couldn't be delayed

Report Shows Increasing Use of Innovative Contracts…

The Alliance for Regenerative Medicine (ARM) explores practical steps to improve patient access to Advanced Therapy Medicinal Products (ATMPs) in Europe through innovative contracting methods in its latest report: "Innovative Contracting for ATMPs in Europe: Recent Learning from the Manufacturer Experiences"ARM notes a rise in innovative contracting for ATMPs in Europe over the past five years and conducted interviews and workshops with industry representatives, including seven out of the ten manufacturers that obtained marketing authorization for ATMPs in Europe since 2018Challenges in health technology assessment (HTA), pricing fluctuations, and the need for early dialogues between stakeholders are key issues in the adoption of innovative contracts for ATMPs, emphasizing the importance of trust-building between payers and manufacturers for successful implementation

Compulsory Discounts are a “Bureaucratic Monster,”…

The new compulsory discounts in the GKV-FinStG do not consider the economic consequences and the cumulative effects of savings measures, according to the Federal Association of the Pharmaceutical Industry (BPI)The BPI argues that the GKV-FinStG also has negative effects on the security of supply for innovative medicines, especially for patients with rare diseases, and it has become a "price-setting process" dominated by statutory health insuranceThe BPI calls for subsequent adjustments to the GKV-FinStG, stating that it contradicts the goals of the federal government and has a negative impact on Germany as a location for innovation and research

Boehringer Withdraws Spevigo in Germany Due to…

Boehringer Ingelheim has withdrawn Spevigo (spesolimab) for the treatment of generalized pustular psoriasis in Germany, after the therapy's added benefit was deemed "Not Proven" by the Federal Joint Committee (G-BA)Boehringer plans to challenge the benefit assessment in court, expressing concerns that the German system could lead to a loss of competitiveness in the healthcare industry and impact patient careSpeaking to NAVLIN Daily, the company called G-BA’s decision “fundamentally flawed,” suggesting that it is “indicative of a rigid benefit assessment process that does not prioritize patient needs"

30 Drugs Could Suffer Under GKV-FinStG Rules in Next 2…

As the comment period on the effects of the GKV Financial Stabilization Act (GKV-FinStG) comes to a close, the German industry Association of Research-Based Drug Manufacturers (vfa) has once again floated concerns that the bill will lead to negative consequences for patient care and the pharmaceutical industry, with delays in introducing innovative medicines and potential job lossesThe group’s new research suggests that up to 30 products or approvals could be negatively affected by the measures in the next two yearsOverall, the vfa called the bill "alarming," adding, "It is already clear that patients in Germany will have to live with treatment restrictions in the future because medicines are withdrawn from the market or are not even brought onto the market."

Connect With Our Team Of Global Experts

Contact Us

Feel free to get in touch with us via email, live chat, or schedule a meeting!